Combatting HIV Or Other STIs Early (CHOOSE)
Westat · with Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA) · NCT07510048
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 13–24 · Men only
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 200
- US sites recruiting
- 6
- Study start
- September 16, 2026
- Record last updated
- October 9, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The overarching goal of this project is to optimize the PrEP Choice integrated mHealth package and assess the efficacy and cost of PrEP Choice on PrEP initiation and adherence among young people. It is hypothesized that PrEP Choice will improve HIV PrEP uptake and adherence among young people and will be cost-effective to deliver to young people in the United States (U.S.). This study will also assess the uptake, adherence, and acceptability of DoxyPEP among young people.
Being studied: Standard of care and PrEP Choice at Enrollment; Standard of care followed by PrEP Choice at Month 9
Conditions: HIV; STIs; STIs Prevention; HIV Prevention
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age 13-24 years, inclusive;
- Self-reports being at increased likelihood for HIV acquisition, defined as having anal sex with a male in their lifetime;
- Owns an iOS or Android Smartphone and able to access all elements of the PrEP Choice package;
- Not currently on PrEP and interested in learning more about PrEP;
- Is not living with HIV;
- Weighs at least 35 kg;
- Willing to receive PrEP care from a provider at a participating ATN SC;
- Able to understand, read, and speak English;
- Able to participate at the study site; and
- Willing and able to provide written informed consent.
- If of legal age or otherwise able to provide independent informed consent as determined by local law and consistent with IRB policies: Willing and able to provide written informed consent for study participation.
- If not of legal age or otherwise not able to provide independent informed consent as determined by local law and consistent with IRB policies: Parent or legal guardian is willing and able to provide written informed consent for study participation and potential participant is willing and able to provide written assent for study participation.
Exclusion Criteria
- Female;
- In a mutually monogamous sexual relationship with a partner not living with HIV for the past 12 months;
- Currently participating in an interventional trial of PrEP agents, or prior enrollment in HPTN 083, HPTN 083-01, or any other study of long-acting PrEP (including PURPOSE- 2 lenacapavir study);
- Plan to move within 18 months to an area inaccessible to a participating ATN SC;
- An employee of the participating SC; or
- Any concurrent participation in other clinical trials or behavioral intervention studies without prior approval from the protocol team.
- Any other medical, behavioral, or other conditions that in the opinion of the SC Project Lead could interfere with adherence to study procedures or the individual's ability to remain in the study for an 18-month period or compromise interpretation of study results.
Recruiting US locations
San Francisco Department of Public Health
San Francisco, CA 94102
Site contact: Emily Schaeffer · 628-217-7456 · emily.schaeffer@sfdph.org
Children's National Medical Center
Washington D.C., DC 20010
Site contact: Justin Unternaher · 202-476-1030 · junternahe@childrensnational.org
University of South Florida
Tampa, FL 33612
Site contact: Elizabeth Enriquez-Bruce · 813-250-2574 · enriquezbruce@usf.edu
University Illinois Chicago
Chicago, IL 60612
Site contact: Rachel Jackson · 312-996-6018 · rjacks34@uic.edu
Tulane University
New Orleans, LA 70112
Site contact: Leslie Kozina · 504-988-5348 · lkozina@tulane.edu
St. Jude Children's Research Hospital
Memphis, TN 38015
Site contact: Mary Dillard · 901-595-4083 · Mary.dillard@stjude.org
Study contacts (from the official record)
- Erin Healey · 301-610-8703 · ErinHealey@westat.com
- Nancy Liu · 718-980-3937 · NancyLiu@westat.com
Similar studies in California
All healthy volunteers studies in California →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca
- Location
- Glendale, CA + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
- Location
- Rialto, CA + 1 other US site
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
Pfizer
- Location
- Lake Forest, CA + 3 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Phase 1 Study of SBS-147 in Healthy Adults
Sparian Biosciences, Inc
- Location
- Cypress, CA
- Eligibility basics
- Ages 18–55